

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM540627

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Xeris Pharmaceuticals, Inc.		09/10/2019	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Oxford Finance LLC, as Collateral Agent		
<b>Street Address:</b>	133 North Fairfax Street		
<b>Internal Address:</b>	Attn: Legal Department		
<b>City:</b>	Alexandria		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22314		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 16</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87571175	GLUCAPEN	
<b>Serial Number:</b>	87636346	GLUCAXER	
<b>Serial Number:</b>	87636352	GLUCAXER HYPOPEN	
<b>Serial Number:</b>	87636355	GLUXERIS	
<b>Serial Number:</b>	87636360	GLUXERIS HYPOPEN	
<b>Serial Number:</b>	88011935	GVOKE	
<b>Serial Number:</b>	88011932	GVOKE HYPOPEN	
<b>Serial Number:</b>	88011936	HYPOGLU	
<b>Serial Number:</b>	88011934	HYPOGLU HYPOPEN	
<b>Serial Number:</b>	87582219	HYPOPEN	
<b>Serial Number:</b>	88011928	MYGLUCA	
<b>Serial Number:</b>	88011924	MYGLUCA HYPOPEN	
<b>Serial Number:</b>	87450253	XERIJECT	
<b>Serial Number:</b>	87450239	XERIS PHARMACEUTICALS	
<b>Serial Number:</b>	87452737	XERIS PHARMACEUTICALS	
<b>Serial Number:</b>	87450263	XERISOL	
<b>CORRESPONDENCE DATA</b>			

CH \$415.00 87571175

**Fax Number:** 8586385130

**Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.**

**Phone:** 619-699-2700

**Email:** susan.reynholds@dlapiper.com

**Correspondent Name:** DLA Piper LLP (US)

**Address Line 1:** 401 B Street, Suite 1700

**Address Line 4:** San Diego, CALIFORNIA 92101

<b>NAME OF SUBMITTER:</b>	Matt Schwartz
---------------------------	---------------

<b>SIGNATURE:</b>	/s/ Matt Schwartz
-------------------	-------------------

<b>DATE SIGNED:</b>	09/12/2019
---------------------	------------

**Total Attachments: 15**

source=IPSA#page1.tif  
source=IPSA#page2.tif  
source=IPSA#page3.tif  
source=IPSA#page4.tif  
source=IPSA#page5.tif  
source=IPSA#page6.tif  
source=IPSA#page7.tif  
source=IPSA#page8.tif  
source=IPSA#page9.tif  
source=IPSA#page10.tif  
source=IPSA#page11.tif  
source=IPSA#page12.tif  
source=IPSA#page13.tif  
source=IPSA#page14.tif  
source=IPSA#page15.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of September 10, 2019 by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (in such capacity, the "Collateral Agent") and XERIS PHARMACEUTICALS, INC., a Delaware corporation with offices located at 180 North LaSalle Street, Suite 1600, Chicago, IL 60601 ("Grantor").

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Amended and Restated Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated of even date herewith (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

180 North LaSalle Street, Suite 1600  
Chicago, IL 60601  
Attn: \_\_\_\_\_

XERIS PHARMACEUTICALS, INC.

By: Boris M. Osterel

Title: CFO

COLLATERAL AGENT:

Address of Lender:

133 North Fairfax Street  
Alexandria, Virginia 22314  
Attn: Legal Department

OXFORD FINANCE LLC

By: \_\_\_\_\_

Title: \_\_\_\_\_

*{Signature Page to Intellectual Property Security Agreement}*

EAST\168710299

**TRADEMARK**  
**REEL: 006743 FRAME: 0544**

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

180 North LaSalle Street, Suite 1600  
Chicago, IL 60601  
Attn: \_\_\_\_\_

XERIS PHARMACEUTICALS, INC.

By: \_\_\_\_\_

Title: \_\_\_\_\_

COLLATERAL AGENT:

Address of Lender:

133 North Fairfax Street  
Alexandria, Virginia 22314  
Attn: Legal Department

OXFORD FINANCE LLC

By:  \_\_\_\_\_ Colette H. Featherly

Title: Senior Vice President \_\_\_\_\_

*[Signature Page to Intellectual Property Security Agreement]*

EAST\168710299

**TRADEMARK**  
**REEL: 006743 FRAME: 0545**

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

**EXHIBIT B**

Patents

Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	United Arab Emirates	1426/2014	6/27/2013		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Australia	2013284412	6/27/2013	2013284412	4/5/2018
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Brazil	BR112014032695-9	6/27/2013		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Canada	2877909	6/27/2013		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Hong Kong	15105341.8	6/27/2013	HK1204771	6/15/2018
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	China	201380034240.7	6/27/2013	ZL201380034240.7	12/1/2017
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	China	201711091408.4	6/27/2013		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Austria	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Germany	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Denmark	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	France	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	United Kingdom	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Ireland	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Netherlands	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Norway	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	European Patent Office	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Sweden	13736714.0	6/27/2013	2874599	5/1/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Israel	236393	6/27/2013		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	India	10985/DELN P/2014	6/27/2013		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Japan	2015-520527	6/27/2013	6416760	10/12/2018
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Japan	2018-189056	6/27/2012		

Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Republic of Korea	10-2015-7002262	6/27/2013		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	Mexico	MX/a/2014/015944	6/27/2013	345256	1/23/2017
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	United States of America	13/829937	3/14/2013	9125805	9/8/2015
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS	United States of America	14/812515	7/29/2015		
PHARMACEUTICAL FORMULATIONS FOR REDUCING INJECTION SITE REACTIONS	United States of America	62/728947	9/10/2018		
FORMULATIONS FOR THE TREATMENT OF DIABETES	United Arab Emirates	0419/2014	10/31/2012		
FORMULATIONS FOR THE TREATMENT OF DIABETES	Australia	2012332556	10/31/2012	2012332556	9/8/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Brazil	BR112014010275-9	10/31/2012		
FORMULATIONS FOR THE TREATMENT OF DIABETES	Canada	2853942	10/31/2012		
FORMULATIONS FOR THE TREATMENT OF DIABETES	China	201280053399.9	10/31/2012	ZL201280053399.9	5/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Eurasian Patent Organization	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Armenia	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Azerbaijan	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Belarus	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Kyrgyz Republic	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Kazakhstan	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Russian Federation	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Tajikistan	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Turkmenistan	201490913	10/31/2012	027744	8/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Belgium	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Switzerland	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Germany	12798470.6	10/31/2012	2773331	2/10/2016



Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
FORMULATIONS FOR THE TREATMENT OF DIABETES	Denmark	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Spain	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	France	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	United Kingdom	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Hong Kong	14110412.3	10/31/2012	HK1196953	8/12/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Italy	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Netherlands	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	European Patent Office	12798470.6	10/31/2012	2773331	2/10/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Indonesia	P00201403186	10/31/2012	IDP000050775	4/17/2018
FORMULATIONS FOR THE TREATMENT OF DIABETES	Israel	232294	10/31/2012	232294	9/1/2018
FORMULATIONS FOR THE TREATMENT OF DIABETES	India	3948/DELNP/2014	10/31/2012		
FORMULATIONS FOR THE TREATMENT OF DIABETES	Japan	2014-539160	10/31/2012	6117811	3/31/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	Republic of Korea	10-2014-7014882	10/31/2012	10-2007057	7/29/2019
FORMULATIONS FOR THE TREATMENT OF DIABETES	Republic of Korea	10-2019-7021542	10/31/2012		
FORMULATIONS FOR THE TREATMENT OF DIABETES	Mexico	MX/a/2014/05311	10/31/2012		
FORMULATIONS FOR THE TREATMENT OF DIABETES	Singapore	11201401921Y	10/31/2012	11201401921Y	1/28/2016
FORMULATIONS FOR THE TREATMENT OF DIABETES	Thailand	1401002311	10/31/2012		
FORMULATIONS FOR THE TREATMENT OF DIABETES	United States of America	14/354848	10/31/2012	9138479	9/22/2015
FORMULATIONS FOR THE TREATMENT OF DIABETES	Vietnam	1201401767	10/31/2012	17979	12/5/2017
FORMULATIONS FOR THE TREATMENT OF DIABETES	South Africa	2014/03795	10/31/2012	2014/03795	1/27/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	United Arab Emirates	0960/2013	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Australia	2012225268	3/9/2012	2012225268	2/2/2017
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Australia	2017200295	3/9/2012	2017200295	7/12/2018

Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Brazil	BR112013023062-2	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Canada	2829400	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Hong Kong	14104382.2	3/9/2012	HK1191230	1/6/2017
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	China	201280012645.6	3/9/2012	ZL201280012645.6	5/4/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	China	201610221799.6	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Eurasian Patent Organization	201370178	3/9/2012	028572	12/29/2017
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Hong Kong	18104448.0	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	European Patent Office	12711071.6	3/9/2012	2683364	1/18/2017
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	European Patent Office	17151475.5	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Indonesia	W00201304149	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Israel	228348	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	India	7958/DELNP/2013	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Japan	2013-557930	3/9/2012	6063877	12/22/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Republic of Korea	10-2013-7026683	3/9/2012	10-1978527	5/8/2019
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Mexico	MX/a/2013/010376	3/9/2012	342675	10/7/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Singapore	201306809-3	3/9/2012	193389	3/22/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Thailand	1301005066	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	United States of America	13/417073	3/9/2012	8697644	4/15/2014
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	United States of America	14/188464	2/24/2014	9302010	4/5/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	United States of America	14/192679	2/27/2014	9295724	3/29/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	United States of America	14/192697	2/27/2014	9339545	5/17/2016
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	United States of America	15/077633	3/22/2016		

Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	Vietnam	1-2013-02839	3/9/2012		
STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS	South Africa	2013/06836	3/9/2012	2013/06836	4/29/2015
METHODS FOR RAPIDLY TREATING SEVERE HYPOGLYCEMIA	United States of America	13/826662	3/14/2013	9018162	4/28/2015
COMPOSITIONS FOR RAPIDLY TREATING SEVERE HYPOGLYCEMIA	United States of America	14/676415	4/1/2015	9642894	5/9/2017
USE OF LOW DOSE GLUCAGON	European Patent Office	16751037.9	6/10/2016		
USE OF LOW DOSE GLUCAGON	United States of America	15/735052	6/10/2016		
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	China	20158001809 9.0	2/6/2015		
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Austria	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Germany	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Denmark	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	France	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	United Kingdom	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Ireland	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Netherlands	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Norway	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	European Patent Office	15706976.6	2/6/2015	3102184	1/30/2019
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Japan	2016-550716	2/6/2015		
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	Republic of Korea	10-2016-7023950	2/6/2015		
STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION	United States of America	15/117016	2/6/2015		
INTRACUTANEOUS INJECTION	Australia	2014200476	12/22/2003	2014200476	11/19/2015
INTRACUTANEOUS INJECTION	Australia	2015215889	12/22/2003	2015215889	2/15/2018
INTRACUTANEOUS INJECTION	Canada	2510196	12/22/2003	2510196	4/1/2014
INTRACUTANEOUS INJECTION	European Patent Office	12180169.0	12/22/2003		

Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
INTRACUTANEOUS INJECTION	European Patent Office				
INTRACUTANEOUS INJECTION	Japan	2004-563920	12/22/2003	5591434	8/8/2014
INTRACUTANEOUS INJECTION	Japan	2012-021596	12/22/2003	5964602	7/8/2016
INTRACUTANEOUS INJECTION	United States of America	10/539931	12/22/2003	8110209	2/7/2012
INTRACUTANEOUS PASTE COMPOSITION	United States of America	12/946994	11/16/2010	8790679	7/29/2014
PASTES FOR INJECTION OF A THERAPEUTIC AGENT	United States of America	14/289448	5/28/2014	9314424	4/19/2016
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	Australia	2015300944	8/6/2015		
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	Canada	2957399	8/6/2015		
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	Hong Kong	17110627.1	8/6/2015		
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	China	20158004218 5.5	8/6/2015		
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	European Patent Office	15750582.7	8/6/2015		
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	Japan	2017-506262	8/6/2015		
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	Republic of Korea	10-2017-7006166	8/6/2015		
SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES	United States of America	15/501333	8/6/2015		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN DEOXYGENATED APROTIC POLAR SOLVENTS	United States of America	62/829739	4/5/2019		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Australia	2016326749	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Brazil	BR11201800 5800-9	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS	Canada	2999404	9/25/2016		

Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	China	20168005600 0.0	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Eurasian Patent Organization	201890704	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Egypt	PCT 509/2018	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Hong Kong	18110112.2	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	European Patent Office	16778600.3	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Israel	258298	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	India	20181701146 7	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Japan	2018-515619	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Republic of Korea	10-2018- 7011805	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Mexico	MX/a/2018/0 03705	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	New Zealand	740799	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Saudi Arabia	518391187	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Singapore	11201802358 S	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Thailand	1801001768	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	United States of America	15/136650	4/22/2016	9649364	5/16/2017
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	United States of America	15/594998	5/15/2017		

Description	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS	United States of America	15/763050	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	Vietnam	1-2018-01710	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	South Africa	2018/01912	9/25/2016		
METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS	South Africa	2019/04146	9/25/2016		
PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS	Gulf Co-Operation Council	2018/35426	6/2/2018		
PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS	Taiwan	107118951	6/1/2018		
PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS	United States of America	15/994832	5/31/2018		
PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS	Patent Cooperation Treaty	PCT/US2018/035473	5/31/2018		
TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES	Patent Cooperation Treaty	PCT/US2018/067294	12/21/2018		
METHODS FOR TREATING CONGENITAL HYPERINSULINISM	Patent Cooperation Treaty	PCT/US2018/042197	7/14/2018		
TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON	Patent Cooperation Treaty	PCT/US2019/014815	1/23/2019		
METHOD FOR INJECTING AUTO-GELLING PEPTIDES	United States of America	62/833867	4/15/2019		
STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME	United States of America	62/855134	5/31/2019		

EXHIBIT C

Trademarks

<b>Title</b>	<b>Country</b>	<b>Appl. No.</b>	<b>Appl. Date</b>	<b>Reg. No.</b>	<b>Reg. Date</b>
GLUCAPEN	United States of America	87/571,175	8/16/2017		
GLUCAXER	European Community	017884655	4/6/2018	017884655	8/29/2018
GLUCAXER	United States of America	87/636,346	10/6/2017		
GLUCAXER HYOPEN	European Community	017884652	4/6/2018	017884652	8/29/2018
GLUCAXER HYOPEN	United States of America	87/636,352	10/6/2017		
GLUXERIS	United States of America	87/636,355	10/6/2017		
GLUXERIS HYOPEN	United States of America	87/636,360	10/6/2017		
GVOKE	United Arab Emirates				
GVOKE	Argentina	3767595	12/20/2018		
GVOKE	Argentina	3767594	12/20/2018		
GVOKE	Brazil	916491285	12/21/2018		
GVOKE	Brazil	916491331	12/21/2018		
GVOKE	Canada	1,936,992	12/19/2018		
GVOKE	Madrid Protocol (TM)		12/19/2018	1462300	12/19/2018
GVOKE	Australia		12/19/2018	1462300	12/19/2018
GVOKE	China	88011935	12/19/2018	1462300	12/19/2018
GVOKE	Colombia		12/19/2018	1462300	12/19/2018
GVOKE	European Community		12/19/2018	1462300	12/19/2018
GVOKE	Israel		12/19/2018	1462300	12/19/2018
GVOKE	India		12/19/2018	1462300	12/19/2018
GVOKE	Japan		12/19/2018	1462300	12/19/2018
GVOKE	Republic of Korea		12/19/2018	1462300	12/19/2018
GVOKE	Mexico		12/19/2018	1462300	12/19/2018
GVOKE	Norway		12/19/2018	1462300	12/19/2018
GVOKE	New Zealand		12/19/2018	1462300	12/19/2018
GVOKE	Russian Federation		12/19/2018	1462300	12/19/2018
GVOKE	Saudi Arabia				
GVOKE	United States of America	88/011,935	6/22/2018		

Title	Country	Appl. No.	Appl. Date	Reg. No.	Reg. Date
GVOKE	South Africa	2018/38079	12/19/2018		
GVOKE	South Africa	2018/38080	12/19/2018		
GVOKE HYPOPEN	United Arab Emirates				
GVOKE HYPOPEN	Argentina	3767592	12/20/2018		
GVOKE HYPOPEN	Argentina	3767593	12/20/2018		
GVOKE HYPOPEN	Brazil	916491374	12/21/2018		
GVOKE HYPOPEN	Brazil	916491412	12/21/2018		
GVOKE HYPOPEN	Canada	1,936,993	12/19/2018		
GVOKE HYPOPEN	Madrid Protocol (TM)		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Australia		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Switzerland		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	China	88011932	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Colombia		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	European Community		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Israel		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	India		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Japan		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Republic of Korea		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Mexico		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Norway		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	New Zealand		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Russian Federation		12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	Saudi Arabia				
GVOKE HYPOPEN	United States of America	88/011,932	6/22/2018		
GVOKE HYPOPEN	South Africa	2018/38081	12/19/2018		
GVOKE HYPOPEN	South Africa	2018/38082	12/19/2018		
HYPOGLU	United States of America	88/011,936	6/22/2018		
HYPOGLU HYPOPEN	United States of America	88/011,934	6/22/2018		
HYPOPEN	European Community	017923552	6/27/2018	017923552	11/29/2018
HYPOPEN	United States of America	87/582,219	8/24/2017		
MYGLUCA	United States of America	88/011,928	6/22/2018		
MYGLUCA HYPOPEN	United States of America	88/011,924	6/22/2018		



<b>Title</b>	<b>Country</b>	<b>Appl. No.</b>	<b>Appl. Date</b>	<b>Reg. No.</b>	<b>Reg. Date</b>
XERJECT	European Community	017459199	11/10/2017	017459199	3/12/2018
XERJECT	United States of America	87/450,253	5/15/2017		
XERIS PHARMACEUTICALS	United States of America	87/450,239	5/15/2017		
XERIS PHARMACEUTICALS	United States of America	87/452,737	5/17/2017	5,364,202	12/26/2017
XERISOL	European Community	017459173	11/10/2017	017459173	3/12/2018
XERISOL	United States of America	87/450,263	5/15/2017		